scholarly article | Q13442814 |
P50 | author | Steven Lockhart | Q90942112 |
Jim Buttery | Q105095703 | ||
Richard Moxon | Q24453739 | ||
Jodie McVernon | Q54345981 | ||
Andrew J. Pollard | Q64861148 | ||
P2093 | author name string | Anthony Harnden | |
Anna Riddell | |||
Keith Cartwright | |||
Laura Lane | |||
Tracey Chantler | |||
Linda Diggle | |||
Rhonwen Morris | |||
Jane Bowen-Morris | |||
P433 | issue | 14 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1751-1758 | |
P577 | publication date | 2005-04-01 | |
P1433 | published in | The Journal of the American Medical Association | Q1470970 |
P1476 | title | Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial | |
P478 | volume | 293 |
Q37656908 | A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes |
Q57276295 | A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine |
Q39397815 | A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challe |
Q60469224 | A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial |
Q36732495 | Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability |
Q37099250 | Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom |
Q36797196 | Bacterial meningitis: the impact of vaccination |
Q38911521 | Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine |
Q36446881 | Combination conjugate vaccines |
Q37077660 | Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates |
Q37872958 | Comparative effects of carrier proteins on vaccine-induced immune response |
Q24235722 | Conjugate vaccines for preventing meningococcal C meningitis and septicaemia |
Q24244951 | Conjugate vaccines for preventing meningococcal C meningitis and septicaemia |
Q41812746 | Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response |
Q42248845 | Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain |
Q37951530 | Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules |
Q37769874 | Glycoconjugate vaccines and immune interference: A review |
Q36026108 | Haemophilus influenzae type b reemergence after combination immunization |
Q37163685 | Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone |
Q83374772 | Immunogenicity and safety of CRM₁₉₇ conjugated 9-valent pneumococcal and meningococcal C combination vaccine in healthy infants |
Q79193785 | Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs |
Q39605431 | Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type B vaccine and a meningococcal gro |
Q51824053 | Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. |
Q38183156 | Neisseria meningitidis B vaccines: recent advances and possible immunization policies. |
Q36153895 | New combination vaccines still need a boost |
Q34114188 | Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use. |
Q36600371 | Pneumococcal conjugate vaccines: emerging clinical information and its implications |
Q85115140 | Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines |
Q51963509 | Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. |
Q45393967 | Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, |
Q31158788 | Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data |
Q31049522 | Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. |
Q37613613 | Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity |
Q37621061 | The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. |
Q38160248 | The history of pneumococcal conjugate vaccine development: dose selection |
Q37376987 | The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants |
Q80754930 | WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva |
Q93633809 | What's new in the other general journals |
Search more.